Now Reading: Amneal acquires Kashiv BioSciences creates global biosimilars leader
-
01
Amneal acquires Kashiv BioSciences creates global biosimilars leader
Amneal acquires Kashiv BioSciences creates global biosimilars leader
Telangana Today reports that Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader. The deal combines Kashiv’s biologics R&D and manufacturing with Amneal’s commercial scale.…
The Story in Brief
Telangana Today reports that Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader. The deal combines Kashiv’s biologics R&D and manufacturing with Amneal’s commercial scale. The combined portfolio is expected to support multiple biosimilar launches each year, tapping into more than $300 billion in projected global biologics loss of exclusivity over the next decade. Integration planning is underway. Financial advisers included Goldman Sachs and J.P. Morgan.
The Indian Opinion
The deal is being sold as a leap towards affordable biologic medicines, but biosimilars remain scarce in India. The promise of expanded patient access mostly targets the US market, where high prices fuel demand. For Indian patients, the real test will be whether the combined entity files for approval in India or licences rights to local firms. Without that, the acquisition is just another offshore consolidation.
Source: telanganatoday.com
This story was synthesised by AI from the source linked above.
